In summary, our study demonstrated that miR-192-5p acted as a compensatory protector against dyslipidemia by regulating the YY1/FASN pathway, suggesting that this miRNA could be a potential therapeutic target in NAFLD. This evidence concerns the gene YY1 and metabolic dysfunction-associated steatotic liver disease.